[ARRY] Array BioPharma Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.8 Change: 0.19 (2.21%)
Ext. hours: Change: 0 (0%)

chart ARRY

Refresh chart

Strongest Trends Summary For ARRY

ARRY is in the medium-term up 32% above S&P in 6 months. In the long-term up 323% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company?s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company?s partnered clinical program

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.71 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 9.82% Sales Growth - Q/Q-75.48% P/E-10.59
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.94% ROE-12.23% ROI-3.87%
Current Ratio4.38 Quick Ratio Long Term Debt/Equity0.71 Debt Ratio0.9
Gross Margin-7.14% Operating Margin-5.45% Net Profit Margin-13.45% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities38.85 M Cash From Investing Activities12.56 M Cash From Operating Activities21.47 M Gross Profit-5.54 M
Net Profit58.31 M Operating Profit54.47 M Total Assets208.44 M Total Current Assets196.59 M
Total Current Liabilities44.92 M Total Debt107.98 M Total Liabilities158.29 M Total Revenue6.6 M
Technical Data
High 52 week19.99 Low 52 week12.59 Last close16.82 Last change-2.83%
RSI68.08 Average true range0.92 Beta1.32 Volume2.74 M
Simple moving average 20 days7.82% Simple moving average 50 days6.7% Simple moving average 200 days8.25%
Performance Data
Performance Week-2.72% Performance Month5.32% Performance Quart22.24% Performance Half-1.41%
Performance Year29.68% Performance Year-to-date18.04% Volatility daily3.82% Volatility weekly8.53%
Volatility monthly17.49% Volatility yearly60.59% Relative Volume178.42% Average Volume2.81 M
New High0.46% New Low

News

2019-03-18 08:00:00 | BRAFTOVI® encorafenib in Combination with MEKTOVI® binimetinib and ERBITUX® cetuximab or panitumumab Recommended by the National Comprehensive Cancer Network® NCCN Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer

2019-03-07 12:18:08 | How Financially Strong Is Array BioPharma Inc. NASDAQ:ARRY?

2019-03-06 07:57:00 | Why Array BioPharma Stock Soared 22.9% in February

2019-03-05 16:05:00 | Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

2019-03-05 14:40:34 | 3 Small Caps Posting Big Gains

2019-03-04 08:35:00 | Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-26 13:34:22 | 5 Stocks Seeing Insider Selling Right Now

2019-02-21 16:05:00 | Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

2019-02-14 14:02:07 | Zoetis ZTS Beats on Q4 Earnings & Sales, Shares Up

2019-02-08 08:03:13 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-02-07 06:34:11 | Will Array BioPharma Continue to Surge Higher?

2019-02-06 08:40:01 | Array BioPharma ARRY Soars: Stock Adds 11% in Session

2019-02-06 08:23:47 | The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

2019-02-05 17:01:32 | Edited Transcript of ARRY earnings conference call or presentation 5-Feb-19 2:00pm GMT

2019-02-05 16:19:00 | Array BioPharma Surges as Loss Is Narrower Than Expected

2019-02-05 15:39:00 | Here's What Sent Array BioPharma Soaring 11.3% Today

2019-02-05 14:03:06 | Array Biopharma Inc ARRY Q2 2019 Earnings Conference Call Transcript

2019-02-05 13:14:35 | Boulder biotech firm's skin cancer drugs drive 'strong' second quarter

2019-02-05 10:00:03 | Here's Why Array BioPharma ARRY is a Great Momentum Stock to Buy

2019-02-05 09:52:02 | Array BioPharma ARRY Upgraded to Buy: Here's What You Should Know

2019-02-05 09:15:02 | Array BioPharma ARRY Reports Q2 Loss, Tops Revenue Estimates

2019-02-05 08:12:23 | Array BioPharma: Fiscal 2Q Earnings Snapshot

2019-02-05 08:00:00 | Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019

2019-02-03 11:34:00 | Here's Why Array BioPharma Jumped 31% in January

2019-01-30 12:08:52 | Does Array BioPharma Inc.’s NASDAQ:ARRY CEO Pay Compare Well With Peers?

2019-01-29 16:05:00 | Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019

2019-01-29 10:31:03 | Array BioPharma ARRY May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-01-29 09:30:02 | Has Array BioPharma ARRY Outpaced Other Medical Stocks This Year?

2019-01-26 08:03:32 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-01-18 07:45:12 | Moving Average Crossover Alert: Array BioPharma

2019-01-17 10:00:03 | What Makes Array BioPharma ARRY a Strong Momentum Stock: Buy Now?

2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave

2019-01-15 13:42:28 | Analyst: This Biopharma Stock Could Surge 76%

2019-01-15 08:01:58 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-01-15 07:55:00 | Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS

2019-01-14 17:02:00 | Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer

2019-01-14 08:03:01 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-01-09 08:25:00 | Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?

2019-01-09 08:03:10 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-01-07 15:47:00 | Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today

2018-12-26 08:03:56 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2018-12-21 10:22:21 | Breakeven On The Horizon For Array BioPharma Inc. NASDAQ:ARRY

2018-12-20 16:05:00 | Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-20 08:04:24 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2018-12-18 08:04:47 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2018-12-13 08:04:39 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2018-12-13 07:00:00 | Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma

2018-12-10 00:38:48 | Is Array Biopharma Inc ARRY A Good Stock To Buy?

2018-12-04 08:06:03 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2018-11-30 13:53:25 | Analysts Remain Bullish on Array BioPharma Stock